F98 Stock Overview
A pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CytoMed Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.04 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$1.25 |
| Beta | 0 |
| 11 Month Change | -20.93% |
| 3 Month Change | 47.83% |
| 1 Year Change | -37.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| F98 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.7% | -0.7% | -0.02% |
| 1Y | -37.4% | -17.2% | 8.2% |
Return vs Industry: F98 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: F98 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| F98 volatility | |
|---|---|
| F98 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: F98's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: F98's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Wee Kiat Tan | w2.cytomed.sg |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
CytoMed Therapeutics Limited Fundamentals Summary
| F98 fundamental statistics | |
|---|---|
| Market cap | €25.04m |
| Earnings (TTM) | -€2.18m |
| Revenue (TTM) | €318.90k |
78.5x
P/S Ratio-11.5x
P/E RatioIs F98 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| F98 income statement (TTM) | |
|---|---|
| Revenue | S$447.70k |
| Cost of Revenue | -S$161.00 |
| Gross Profit | S$447.86k |
| Other Expenses | S$3.51m |
| Earnings | -S$3.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 100.04% |
| Net Profit Margin | -684.21% |
| Debt/Equity Ratio | 4.2% |
How did F98 perform over the long term?
See historical performance and comparison